SINGAPORE – Cancer antibody developer Hummingbird Bioscience obtained approval from the Singapore Government of Fitness to begin a clinical trial for coVID-19 antibody treatment.
The first trials are underway, while a phase 3 trial is scheduled for the end of the year. The most recent trial will investigate the protection and efficacy of the experimental remedy HMBD-115, the company said.
Preclinical studies have shown that HMBD-115 reduces viral load, reduces inflammatory responses related to serious illnesses and lung damage and increases survival, Hummingbird said.
HMBD-115 has also been shown to be joined with maximum potency to all non-unusual strains of coronavirus, adding the D614G variant, which has the dominant strain in the world.
Hummingbird Bioscience, founded in 2015 in Singapore, is using systems biology to expand an antibody discovery platform that can, as it should be, identify key targets on sick mobiles, design molecules to succeed in those goals, and save you mobile protein replication.
He raised $25 million in a B-series spin led by South Korean conglomerate SK Holdings.
Other shareholders involved in the circular come with personal equity and venture capital firm Heritas Capital and SEEDS Capital, Enterprise Singapore’s investment arm. Previous lenders come with Mirae Asset Venture Investment and GNTech Venture Capital.
This brought the total capital hummingbird raised to $65 million.
To learn about the history of dealStreetAsia, click here.
DealStreetAsia is a monetary fact based in Singapore that focuses on personal capital, venture capital and corporate investment activities in Asia, particularly in Southeast Asia, India and Greater China. Nikkei has a majority stake in the company.
Subscribe to our newsletters to get our stories right in your inbox.
You want an Array subscription. .